TD Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

TD Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,796	Closed	-$137K	–	1228
2024 Q4	$137K	Hold	10,796	–	–	﹤0.01%	1235
2024 Q3	$153K	Hold	10,796	–	–	﹤0.01%	1373
2024 Q2	$149K	Hold	10,796	–	–	﹤0.01%	1348
2024 Q1	$178K	Sell	10,796 -44,400	-80%	-$664K	﹤0.01%	1365
2023 Q4	$806K	Hold	55,196	–	–	﹤0.01%	1222
2023 Q3	$677K	Buy	55,196 +27,598	+100%	+$360K	﹤0.01%	1217
2023 Q2	$330K	Hold	27,598	–	–	﹤0.01%	1326
2023 Q1	$369K	Sell	27,598 -18,734	-40%	-$366K	﹤0.01%	1312
2022 Q4	$997K	Hold	46,332	–	–	﹤0.01%	1144
2022 Q3	$909K	Sell	46,332 -1	-0%	-$21	﹤0.01%	1197
2022 Q2	$829K	Buy	46,333 +8,884	+24%	+$91.7K	﹤0.01%	1212
2022 Q1	$371K	Hold	37,449	–	–	﹤0.01%	1372
2021 Q4	$631K	Buy	37,449 +20,593	+122%	+$423K	﹤0.01%	1355
2021 Q3	$400K	Hold	16,856	–	–	﹤0.01%	1423
2021 Q2	$400K	Buy	+16,856	New	+$352K	﹤0.01%	1411

Other funds holding DAWN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ECM

Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

TD Asset Management's DAWN Position: Q1 2025 in Review

TD Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 10,796 shares — an estimated $137K sold.

TD Asset Management first reported a position in DAWN in Q2 2021 and held it in 15 quarters. The position peaked at $997K in Q4 2022. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

TD Asset Management reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
TD Asset Management sold 10,796 Day One Biopharmaceuticals shares in Q1 2025, an estimated $137K.
TD Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 15 quarters.
TD Asset Management's Day One Biopharmaceuticals position peaked at $997K in Q4 2022.
184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.